Find Nitroaspirin manufacturers, exporters & distributors on PharmaCompass

Nitroaspirin

Nitroaspirin

Synopsis, Chemistry

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 175033-36-0, Ncx-4016, No-aspirin 1, Ncx 4016, [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate, No-asa

Molecular Formula

C₁₆H₁₃NO₇

Molecular Weight

331.28 g/mol

InChI Key

IOJUJUOXKXMJNF-UHFFFAOYSA-N

FDA UNII

EH04H13L6B

Nitric Oxide-Releasing Acetylsalicylic Acid Derivative is a nitric oxide (NO) donating derivative of acetylsalicylic acid with anti-inflammatory, analgesic, antipyretic, antithrombotic, gastroprotective and potential antitumor activities. The acetylsalicylic acid derivative moiety of this agent inhibits the activities of cyclooxygenase (COX) I and II, preventing the formation of prostaglandins and thromboxanes. A reduction in prostaglandin synthesis accounts for this agent's anti-inflammatory, anti-pyretic and analgesic activities; a reduction in thromboxane A2 synthesis results in an irreversible inhibition of platelet aggregation. NO donation by this agent, after cleavage from the acetylsalicylic acid derivative in vivo, may protect the gastric mucosa against the damaging effects of the aspirin derivative by modulating prostaglandins. In tumor cells, the NO donating moiety may block the cell cycle in the G1 and G2 phases and may induce apoptosis through caspase-mediated mechanisms.

1 2D Structure

Nitroaspirin

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate

2.1.2 InChI

InChI=1S/C16H13NO7/c1-11(18)23-15-8-3-2-7-14(15)16(19)24-13-6-4-5-12(9-13)10-22-17(20)21/h2-9H,10H2,1H3

2.1.3 InChI Key

IOJUJUOXKXMJNF-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(=O)OC1=CC=CC=C1C(=O)OC2=CC=CC(=C2)CO[N+](=O)[O-]

2.2 Other Identifiers

2.2.1 UNII

EH04H13L6B

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-acetoxybenzoate-2-(1-nitroxymethyl)phenyl Ester

2. Ncx 4016

3. Ncx-4016

4. Nitric Oxide-releasing Aspirin

2.3.2 Depositor-Supplied Synonyms

1. 175033-36-0

2. Ncx-4016

3. No-aspirin 1

4. Ncx 4016

5. [3-(nitrooxymethyl)phenyl] 2-acetyloxybenzoate

6. No-asa

7. 3-((nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate

8. Eh04h13l6b

9. Benzoic Acid, 2-(acetyloxy)-, 3-((nitrooxy)methyl)phenyl Ester

10. 3-[(nitrooxy)methyl]phenyl 2-(acetyloxy)benzoate

11. M-no-asa

12. Benzoic Acid, 2-(acetyloxy)-, 3-[(nitrooxy)methyl]phenyl Ester

13. 3-(nitroxymethyl)phenyl 2-acetoxybenzoate

14. M-no-aspirin

15. Nitric Oxide-releasing Aspirin

16. 2-acetoxybenzoate-2-(1-nitroxymethyl)phenyl Ester

17. 2-((nitrooxy)methyl)phenyl 2-(acetyloxy)benzoate

18. 2-acetoxybenzoic Acid 3-nitrooxymethylphenyl Ester

19. Unii-eh04h13l6b

20. Benzoic Acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl Ester

21. Schembl19524

22. Chembl374385

23. Gtpl9018

24. Zinc22315

25. Dtxsid60938618

26. Ncx4016

27. Chebi:125482

28. Bcp24321

29. Benzoic Acid,2-(acetyloxy)-, 3-[(nitrooxy)methyl]phenyl Ester

30. Akos025294730

31. Ccg-208118

32. Db12445

33. Hy-123823

34. 3-((nitrooxy)methyl)phenyl2-acetoxybenzoate

35. Cs-0086219

36. Ft-0673020

37. Ncx 4016, >=98% (hplc)

38. 3-((nitrooxy)methyl)phenyl 2-acetoxybenzoate

39. 2-acetoxy Benzoic Acid-3-nitrooxymethyl Phenyl Ester

40. J-011058

41. Q3877377

42. Brd-k08807999-001-01-6

43. 2-(acetyloxy)-(3-(nitroxymethyl)phenyl)benzoic Acid

44. (2-{[(1s)-1-(5-fluoro(2-pyridyl))ethyl]amino}-5-chloropyrimidin-4-yl)[5-(methylethoxy)pyrazol-3-yl]amine

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₁₆H₁₃NO₇
Molecular Weight	331.28 g/mol
XLogP3	2.9
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	7
Exact Mass	331.06920175 g/mol
Monoisotopic Mass	331.06920175 g/mol
Topological Polar Surface Area	108 Å²
Heavy Atom Count	24
Formal Charge	0
Complexity	462
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)

Cysteine Proteinase Inhibitors

Exogenous and endogenous compounds which inhibit CYSTEINE ENDOPEPTIDASES. (See all compounds classified as Cysteine Proteinase Inhibitors.)

Anti-Inflammatory Agents, Non-Steroidal

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)

Fibrinolytic Agents

Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)